Healthy behaviors may cut colorectal cancer risk, study says | Fear of IBS symptoms has significant effect on quality of life | Study suggests beneficial effects of decaf coffee on liver
Web Version
October 15, 2014
CONNECT WITH ACG®  FacebookTwitter
Digestive Health SmartBrief
From Stanley K. Fergus and the American College of Gastroenterology

Top Story
Healthy behaviors may cut colorectal cancer risk, study says
Keeping abdominal fat in check, maintaining a healthy weight, getting regular exercise, not smoking, limiting alcohol and eating a healthy diet may all help to reduce the risk of colorectal cancer, according to a study from the German Institute of Human Nutrition Potsdam-Rehbruecke. Researchers said data from 347,237 people estimated that up to 22% of colorectal cancer cases in men and 11% in women may have been prevented if people had followed all of the healthy behaviors. Science World Report (10/10)
Share: LinkedInTwitterFacebookGoogle+Email
Guide to Healthy Living
Fear of IBS symptoms has significant effect on quality of life
The fear people have over symptoms of irritable bowel syndrome may have a stronger effect on their quality of life than the disease's actual symptoms, University of Buffalo researchers reported in The American Journal of Gastroenterology. "Understanding the predictors of QOL can strengthen gastroenterologists' ability to accurately assess, understand and manage more severe IBS patients seen in specialty care settings," researcher Jeffrey Lackner said. Healio (free registration)/Gastroenterology (10/8)
Share: LinkedInTwitterFacebookGoogle+Email
Study suggests beneficial effects of decaf coffee on liver
A National Cancer Institute study found drinking three or more cups of decaffeinated coffee each day may have an effect on enzymes that leads to better liver health. The study adds to earlier research showing caffeinated coffee may also protect the liver, suggesting caffeine may not be the key factor. HealthDay News (10/10)
Share: LinkedInTwitterFacebookGoogle+Email
Household environment may affect EoE risk, study says
Household environment may be part of the reason why eosinophilic esophagitis tends to cluster in families, according to a study from researchers at Cincinnati Children's Hospital Medical Center. The study suggested that the effects of genetics have been overestimated, overshadowing the importance of household environment elements. Healio (free registration) (10/9)
Share: LinkedInTwitterFacebookGoogle+Email
Bariatric surgery spurs greater weight loss, diabetes remission
An analysis showed bariatric surgery was associated with greater weight loss and type 2 diabetes remission in patients than nonsurgical methods such as dieting and behavioral therapy. However, researchers said the findings warrant further assessment on the duration of diabetes remission, the frequency of related complications and long-term health outcomes. Reuters (10/9)
Share: LinkedInTwitterFacebookGoogle+Email
Diagnosis & Treatment
Oral pill found to be effective fecal transplant method
A Massachusetts General Hospital study suggests taking frozen fecal matter in capsule form is as effective as fecal transplant via colonoscopy or a nasogastric tube for patients with Clostridium difficile infections. Diarrhea resolved in 14 of 20 C. diff patients who took the capsules for two days, and they were symptom-free for approximately eight weeks, though one patient relapsed. Symptoms of five of six nonresponders resolved after being treated a second time. The pills had no serious adverse effects. (10/11), The Inquisitr (10/12), The Washington Post (tiered subscription model)/Speaking of Science blog (10/11), Los Angeles Times (tiered subscription model)/Science Now blog (10/11)
Share: LinkedInTwitterFacebookGoogle+Email
FDA approves combination therapy for HCV
Gilead's daily fixed-dose combination of ledipasvir and sofosbuvir has been approved by the FDA as a treatment for adults with chronic hepatitis C infections. The drug follows controversy over the high pricing of sofosbuvir. The new drug is priced at $1,125 a pill, which aligns with the total cost of sofosbuvir plus other treatments. Many patients will undergo eight weeks of treatment with the new combination, totaling about $63,000. Sofosbuvir is taken for 12 weeks. The New York Times (tiered subscription model) (10/11), MedPage Today (free registration) (10/10), (10/10)
Share: LinkedInTwitterFacebookGoogle+Email
Drugmaker wins final FDA approval for ulcerative colitis foam
Salix Pharmaceuticals was granted final approval by the FDA to market its budesonide rectal foam as a treatment for mild to moderately active distal ulcerative colitis. The medicine will likely enter the U.S. market early next year. Healio (free registration)/Gastroenterology (10/8)
Share: LinkedInTwitterFacebookGoogle+Email
C. difficile after liver transplant leads to poor outcomes
Patients who develop Clostridium difficile infections after liver transplants are at increased mortality risk, according to a study presented at the IDWeek 2014 conference on infectious diseases. Underlying end-stage liver disease, nonalcoholic steatohepatitis-based liver disease and co-infection with HIV and hepatitis C were risk factors for C. difficile after transplants, according to the 192-patient study. Healio (free registration) (10/9)
Share: LinkedInTwitterFacebookGoogle+Email
Clinical Trial Monitor
A selection of U.S. based clinical trials seeking participants
Dual epidermal growth factor receptor inhibition with erlotinib and panitumumab with or without chemotherapy for advanced colorectal cancer
Illinois, Indiana, Kansas, Nebraska, New Jersey, Oklahoma, Tennessee.
Share: LinkedInTwitterFacebookGoogle+Email
Safety and efficacy of sofosbuvir + ribavirin in adolescents and children with genotype 2 or 3 chronic HCV infection
California, District of Columbia, Florida, Georgia, Indiana, Maryland, Massachusetts, Missouri, New York, Ohio, Pennsylvania, Texas, Washington, West Virginia, Australia, Germany, Italy, New Zealand, Russian Federation, United Kingdom.
Share: LinkedInTwitterFacebookGoogle+Email
Preliminary evaluation of Septin9 in patients with hereditary colon cancer syndromes
Share: LinkedInTwitterFacebookGoogle+Email
Study of CB-183,315 in patients with Clostridium difficile-associated diarrhea
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Montana, New Jersey, New York, North Carolina, North Dakota, Ohio, Pennsylvania, Texas, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Israel, Italy, Poland, Spain, Sweden, United Kingdom.
Share: LinkedInTwitterFacebookGoogle+Email
Clinical management with SPM system and validation of the SPM 5 hour cutoff in patients with symptoms of gastroparesis
California, Florida, Georgia, Indiana, Massachusetts, Michigan, Pennsylvania, Tennessee, Texas, Vermont.
Share: LinkedInTwitterFacebookGoogle+Email
Did you know?
Behavioral therapy may ease IBS symptoms
"Behavioral therapy has been shown to relieve some IBS symptoms in many people who try it. This broad term covers a variety of therapies, including relaxation therapy, biofeedback, hypnosis, cognitive behavioral therapy, and traditional psychotherapy. Therapy has limitations, however. Some studies have found it does not help relieve constipation or constant abdominal aches that come with IBS." -- WebMD
Share: LinkedInTwitterFacebookGoogle+Email
The Last Word
News and information from the American College of Gastroenterology
How to handle belching, bloating and flatulence
Ever wonder why you experience belching, bloating and flatulence from time to time? Although intestinal gas is unavoidable, you may be able to alleviate the symptoms by following some helpful tips.
Share: LinkedInTwitterFacebookGoogle+Email
To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment."
-- Ralph Waldo Emerson,
American writer
Share: LinkedInTwitterFacebookGoogle+Email
Contact Your Doctor
Stanley K. Fergus
Gastroenterolgy Associates of West Tennessee
1400 Kings Boulevard
Memphis, TN 38105

Phone: (901) 555-1234
Contact ACG
American College of Gastroenterology
P.O. Box 342260
Bethesda, MD 20827-2260
The presence of any advertisement in this newsletter does not constitute endorsement of the associated service, product, or company by the American College of Gastroenterology, SmartBrief, or any participating physicians.
The information contained in Digestive Health SmartBrief is not intended to be medical advice. Consult your physician before making any decisions regarding your health care.
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tara Rosenzweig
Advertising:  Rebecca Adelson
  P: 202.618.5665

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information